111 related articles for article (PubMed ID: 10561015)
21. [Medicinal therapy of malignant lymphomas].
Aul C; Schroeder M; Giagounidis A
Radiologe; 2002 Dec; 42(12):943-53. PubMed ID: 12486548
[TBL] [Abstract][Full Text] [Related]
22. The role of the anti-CD20 antibody rituximab in hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.
Naparstek E
Curr Hematol Rep; 2005 Jul; 4(4):276-83. PubMed ID: 16009042
[TBL] [Abstract][Full Text] [Related]
23. [Non-cytostatic treatment of malignancies. Anti-CD20 monoclonal antibody (Rituximab, Mabthera) in the treatment of non-Hodgkin's lymphoma].
Mayer J; Navrátil M; Vásová J; Vorlícek J
Vnitr Lek; 2001 Sep; 47 Suppl 1():57-62. PubMed ID: 11693064
[TBL] [Abstract][Full Text] [Related]
24. Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.
Hernandez-Ilizaliturri FJ; Jupudy V; Ostberg J; Oflazoglu E; Huberman A; Repasky E; Czuczman MS
Clin Cancer Res; 2003 Dec; 9(16 Pt 1):5866-73. PubMed ID: 14676108
[TBL] [Abstract][Full Text] [Related]
25. Rituximab (MabThera) for aggressive non-Hodgkin's lymphoma.
Eur J Cancer Care (Engl); 2003 Dec; 12(4):306-7. PubMed ID: 14982308
[No Abstract] [Full Text] [Related]
26. [Is lymphoma curable with antibody therapy?].
Leppä S; Nyman H; Karjalainen-Lindsberg ML
Duodecim; 2009; 125(3):267-73. PubMed ID: 19341039
[TBL] [Abstract][Full Text] [Related]
27. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma.
Grillo-López AJ; White CA; Varns C; Shen D; Wei A; McClure A; Dallaire BK
Semin Oncol; 1999 Oct; 26(5 Suppl 14):66-73. PubMed ID: 10561020
[TBL] [Abstract][Full Text] [Related]
28. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
[TBL] [Abstract][Full Text] [Related]
29. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
30. Inotuzumab ozogamicin as novel therapy in lymphomas.
Wong BY; Dang NH
Expert Opin Biol Ther; 2010 Aug; 10(8):1251-8. PubMed ID: 20528256
[TBL] [Abstract][Full Text] [Related]
31. Ofatumumab in the treatment of non-Hodgkin's lymphomas.
Karlin L; Coiffier B
Expert Opin Biol Ther; 2015 Jul; 15(7):1085-91. PubMed ID: 26043777
[TBL] [Abstract][Full Text] [Related]
32. Pathologic prognostic factors in diffuse aggressive non-Hodgkin's lymphoma.
Gascoyne RD
Hematol Oncol Clin North Am; 1997 Oct; 11(5):847-62. PubMed ID: 9336718
[TBL] [Abstract][Full Text] [Related]
33. New biologic markers in non-Hodgkin's lymphomas.
Grogan TM; Miller TP
Hematol Oncol Clin North Am; 1991 Oct; 5(5):925-33. PubMed ID: 1938761
[TBL] [Abstract][Full Text] [Related]
34. Prognostic Factors in Aggressive Non-Hodgkin's Lymphomas.
Nicolaides C; Dimou S; Pavlidisa N
Oncologist; 1998; 3(3):189-197. PubMed ID: 10388103
[TBL] [Abstract][Full Text] [Related]
35. Treatment advances in non-Hodgkin's lymphoma.
Tan BR; Bartlett NL
Expert Opin Pharmacother; 2000 Mar; 1(3):451-66. PubMed ID: 11249530
[TBL] [Abstract][Full Text] [Related]
36. The current status and future impact of targeted therapies in non-Hodgkin lymphoma.
Ujjani C; Cheson BD
Expert Rev Hematol; 2013 Apr; 6(2):191-202; quiz 203. PubMed ID: 23547867
[TBL] [Abstract][Full Text] [Related]
37. New therapeutic targets and drugs in non-Hodgkin's lymphoma.
Sawas A; Diefenbach C; O'Connor OA
Curr Opin Hematol; 2011 Jul; 18(4):280-7. PubMed ID: 21654386
[TBL] [Abstract][Full Text] [Related]
38. In vivo drug-response in patients with leukemic non-Hodgkin's lymphomas is associated with in vitro chemosensitivity and gene expression profiling.
Chow KU; Nowak D; Kim SZ; Schneider B; Komor M; Boehrer S; Mitrou PS; Hoelzer D; Weidmann E; Hofmann WK
Pharmacol Res; 2006 Jan; 53(1):49-61. PubMed ID: 16213748
[TBL] [Abstract][Full Text] [Related]
39. Update: lymphoid neoplasms--molecular characterizations of non-Hodgkin's lymphomas: impact on patient management.
Chappuis PO; Sappino AP
Semin Hematol; 1995 Jul; 32(3):237-41. PubMed ID: 7570067
[No Abstract] [Full Text] [Related]
40. Progress in the non-Hodgkin's lymphomas.
Yuen AR
Ann Oncol; 1999; 10 Suppl 6():19-22. PubMed ID: 10676549
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
